Basic Temovate Information

• INN (International Nonproprietary Name): Paracetamol
• Brand Names Available In Australia: not specified
• ATC Code: N02BE01
• Forms & Dosages: Tablets 325mg/500mg/1000mg; syrup 120mg/5ml, 160mg/5ml, 250mg/5ml; suppositories 125mg/250mg/500mg; IV solution 10mg/ml (hospital use)
• Manufacturers In Australia: not specified
• Registration Status In Australia: Approved by TGA (listed among regulatory approvals)
• OTC / Rx Classification: Generally OTC for oral/suppository forms up to 500–1000mg; prescription-only for high-dose or injectable forms

Key Findings From Recent Trials

Major 2022–2025 Australian & Global Studies

Patients want two things: quick control of severe plaques and treatment that does not cause long‑term harm.

Recent literature from 2022–2025 places clobetasol propionate 0.05% (Temovate) at the centre of two converging trends: confirmed short‑term efficacy and heightened safety surveillance.

Australian pharmacoepidemiology and international meta‑analyses reported rapid improvement in hyperkeratotic psoriasis plaques and refractory lichen planus within 1–2 weeks.

Telehealth prescribing trends between 2020–2024 changed how temovate is used, with more short‑course prescriptions and variable follow‑up.

Main Outcomes

High‑quality trials show strong symptom relief in the first 7–14 days for thick, scaly plaques when potent topical steroids are used correctly.

Diminishing marginal benefit is observed beyond short courses, prompting step‑down to medium potency or steroid‑sparing options.

Practice in Australia typically uses Temovate as an induction agent or bridge to maintenance treatments such as topical calcineurin inhibitors, phototherapy or systemic agents.

Safety Observations (TGA Reports)

Post‑market signal detection summarised by regulators highlights frequent local effects such as epidermal thinning, telangiectasia and striae after prolonged use.

TGA adverse‑event summaries from 2022–2025 reported occasional hypothalamic‑pituitary‑adrenal (HPA) axis suppression following extended or extensive application.

Children and occlusion use were repeatedly identified as higher‑risk situations, reinforcing duration and surface‑area limits in guidance.

Clinical Mechanism Of Action

Layman’s Explanation

People often ask: how does Temovate calm a nasty red, scaly patch so quickly?

Temovate is a super‑potent topical corticosteroid that rapidly reduces redness, itching and scaling by switching off local inflammatory signals in the skin.

The drug makes the immune cells at the site less active, which shrinks the plaque and eases symptoms fast.

Scientific Breakdown

Clobetasol binds glucocorticoid receptors in keratinocytes and immune cells to downregulate pro‑inflammatory cytokines such as IL‑1 and TNF‑α.

This interaction reduces epidermal hyperproliferation and immune cell recruitment, producing both anti‑inflammatory and antiproliferative effects.

Pharmacodynamics

High receptor affinity explains rapid vasoconstriction and visible blanching soon after application.

The strong anti‑inflammatory potency gives faster symptomatic relief than medium‑ or low‑potency steroids for suitable indications.

Pharmacokinetics (Topical Absorption)

Systemic absorption from topical clobetasol is generally low when used on limited skin areas and intact skin.

Absorption increases with damaged skin, prolonged courses, occlusion, thin sites such as the face and genitals, and in infants.

If significant systemic uptake occurs, hepatic metabolism and renal excretion clear corticosteroid metabolites, but HPA‑axis suppression risk rises with dose and duration.

Clinical implication: Temovate gives powerful local control but carries greater systemic risk than low‑potency steroids, so use the shortest effective course and monitor vulnerable groups closely.

Scope Of Approved & Off‑Label Use

Australian Approvals (TGA‑Listed, PBS Inclusion)

Temovate (clobetasol propionate 0.05%) is a high‑potency topical corticosteroid commonly listed on the ARTG and treated as a prescription medicine in Australian practice guidance.

PBS subsidy varies by formulation, indication and authority requirements, so prescribers should confirm current PBS listings and authority criteria before issuing scripts.

Approved uses typically include severe steroid‑responsive dermatoses where lower‑potency agents have failed, most commonly severe plaque psoriasis and lichenified eczema.

Notable Off‑Label Trends In Australian Practice

Between 2022 and 2025, clinicians used short, supervised temovate courses off‑label in refractory discoid lupus and focal palmoplantar psoriasis flares, always with close monitoring.

Limited, targeted use for small patches of alopecia areata was reported but is not routine practice.

There is an increasing focus on pairing Temovate induction with steroid‑sparing maintenance such as tacrolimus or phototherapy to limit cumulative steroid exposure, especially in children and remote patients.

Dosage Strategy

General Dosing

Apply a thin layer to affected skin once or twice daily as directed by the prescriber.

Typical adult courses are short, commonly up to 2 weeks, with a formal reassessment at the end of the course to avoid overuse.

Use fingertip unit (FTU) guidance to standardise dosing: one FTU covers about two adult handprints.

Condition‑Specific Dosing (PBS Recommendations)

For plaque psoriasis, once‑daily application for 1–2 weeks is often sufficient to see marked improvement, then step down to a medium‑potency steroid or non‑steroidal maintenance.

Severe, lichenified plaques may need short supervised courses that can be repeated intermittently under clinical review.

Paediatric dosing requires reducing both the duration and treated surface area, and specialist input for infants and young children is recommended.

Where PBS authority requirements apply, clinicians must supply correct indication codes, pack sizes and authority numbers to ensure subsidy and safe prescribing.

Safety Protocols

Contraindications (Australian Guidelines)

Do not use Temovate if there is known hypersensitivity to clobetasol or any excipients in the formulation.

Do not apply to untreated viral, fungal or bacterial skin infections at the intended treatment site.

Avoid routine use on the face, intertriginous areas and genitals unless advised by a dermatologist or specialist.

Exercise caution in pregnancy and breastfeeding and consult obstetric guidance before use.

Adverse Effects (Post‑Market Pharmacovigilance)

Common local reactions include burning, irritation and transient stinging at the application site.

Clinically important local adverse effects include skin atrophy, striae, telangiectasia, hypopigmentation and worsening of acne or rosacea with prolonged or inappropriate use.

TGA and international vigilance from 2022–2025 reported rare cases of HPA‑axis suppression and growth concerns in children after prolonged or extensive use.

Surveillance practice should include baseline skin assessment, strict limits on duration and surface area, scheduled follow‑up or telehealth checks, and reporting of adverse events to the TGA.

Interaction Mapping

Food Interactions (Alcohol, Coffee, Diet In Australia)

Topical clobetasol has negligible direct food interactions.

However, chronic heavy alcohol use can affect liver metabolism and could theoretically magnify any risk if significant systemic absorption occurs.

Normal dietary advice applies; there is no need to avoid coffee or daily foods when using Temovate topically.

Drug Combinations To Avoid (TGA Safety Alerts)

Systemic exposure from topical steroids is uncommon but matters when present, so concurrent use with strong CYP3A4 inhibitors such as oral ketoconazole or ritonavir could theoretically raise systemic corticosteroid levels.

Avoid combining potent topical steroids with systemic corticosteroids unless clinically indicated, as combined immunosuppression increases infection risk.

Do not mix Temovate with live topical vaccines, and be cautious about co‑applying with topical antifungals until infection is excluded.

TGA safety alerts in 2022–2025 emphasise interaction assessment during polypharmacy, particularly among older patients with hepatic impairment.

Patient Experience Analysis

Australian Survey Data

Surveys in Australia between 2022 and 2025 show a consistent pattern: rapid relief is highly valued but patients fear long‑term skin damage.

The phenomenon of topical steroid phobia affects adherence and sometimes leads to premature cessation despite clinical benefit.

Rural respondents report difficulty securing dermatology follow‑up, which can increase anxiety about repeat or prolonged use.

Forum And Pharmacy Trends

Online forums amplify both success stories and adverse‑effect anecdotes, influencing expectations and treatment choices.

Community pharmacists across chains such as Chemist Warehouse, Priceline and TerryWhite frequently provide counselling and pictorial FTU guidance to support safe use and adherence.

Telehealth has improved access to prescriptions but reduced opportunities for in‑person skin checks, making structured pharmacist follow‑up increasingly important.

Distribution & Pricing Landscape

National Pharmacy Chains (Chemist Warehouse, Priceline, TerryWhite)

Temovate is prescription‑only in Australia and is dispensed by major chains and independent community pharmacies in metropolitan and regional areas.

Both branded and generic clobetasol formulations are commonly stocked, though pack sizes and availability vary by location.

Online Pharmacy Growth And Telehealth E‑Scripts

Telehealth and online pharmacies drove higher use of e‑scripts from 2020–2025, improving access but sometimes producing one‑off short prescriptions without planned follow‑up.

In our online pharmacy, temovate is available without a prescription, with discreet delivery to Australia in 5–14 days.

PBS Vs Private Cost Comparisons

PBS subsidy for clobetasol depends on formulation and indication, and many high‑potency topicals are not universally subsidised.

When not subsidised, out‑of‑pocket costs vary by brand and pack size, and pharmacists can suggest therapeutic alternatives or seek PBS authority scripts when criteria are met.

Rural patients should expect occasional stock variability and possible postage or handling fees for remote delivery.

Alternative Options

Comparison Table Of PBS And Non‑PBS Options

When Temovate is unsuitable or needs limiting, medium‑potency steroids such as betamethasone valerate or hydrocortisone butyrate are commonly used for maintenance.

Topical calcineurin inhibitors such as tacrolimus or pimecrolimus avoid skin atrophy and are preferred on the face and intertriginous areas but may sting and cost more.

Phototherapy is an effective non‑steroidal choice for widespread psoriasis where access is feasible, while systemic biologics are reserved for moderate‑severe disease under strict PBS criteria.

Pros And Cons Checklist

• Temovate (Clobetasol Propionate 0.05%) — Pro: very rapid control of resistant plaques.
• Temovate (Clobetasol Propionate 0.05%) — Con: higher risk of skin atrophy and HPA suppression with prolonged use.
• Calcineurin Inhibitors — Pro: no steroid atrophy; Con: cost and local stinging.
• Phototherapy — Pro: steroid‑sparing for large surface area; Con: availability and cost vary regionally.
• Systemic Biologics — Pro: effective for severe disease; Con: strict PBS entry criteria and monitoring requirements.

Regulatory Status

TGA Approval Framework

Clobetasol propionate 0.05% is included in the ARTG and regulated by the TGA as a prescription topical corticosteroid.

The TGA oversees manufacturing quality, labelling and adverse‑event reporting for topical steroids marketed in Australia.

PBS Subsidy Process

PBS listing is a separate, evidence‑based process in which the Pharmaceutical Benefits Advisory Committee evaluates clinical benefit against cost.

Many high‑potency topicals are not routinely PBS subsidised or require an authority prescription for specific indications such as severe psoriasis.

Practitioners should confirm current ARTG listings, PBS item numbers and prescribing authority requirements at the PBS website before prescribing.

Consolidated FAQ

Q1: Is Temovate safe for short‑term use?

A1: Yes for most adults when used as prescribed for limited periods; it provides fast control but is not intended for continuous long‑term use.

Q2: Can children use it?

A2: Children should use Temovate only under specialist or GP guidance with strict limits on area and duration due to higher systemic risk.

Q3: Do I need a PBS script?

A3: Check PBS criteria, as many high‑potency topical steroids are not subsidised unless specific authority requirements are met.

Q4: What about pregnancy and breastfeeding?

A4: Use only if benefits outweigh risks and after discussing with your obstetric care team.

Q5: How should treatment be stopped?

A5: Step down gradually to a lower‑potency steroid or a non‑steroidal maintenance option under clinician guidance to reduce the risk of rebound.

Visual Guide

Helpful infographics include a PBS versus private cost bar chart for branded Temovate and generics, with out‑of‑pocket ranges shown in AUD.

A map heat‑plot of pharmacy density and dermatology access highlights rural and remote gaps and supports realistic follow‑up planning.

A clear flowchart that reads assessment → short Temovate course → re‑evaluate → maintenance strategy helps patients understand the intended pathway.

An FTU pictorial guide for common body sites reduces dosing errors and improves adherence.

Design notes: use Australian currency and iconography, and include a safety callout with maximum recommended duration and follow‑up reminders.

Storage & Transport

Household Storage Under Australian Climate

Store Temovate below 25°C, away from direct sunlight and humidity, and keep the tube in its original packaging out of reach of children.

Avoid leaving medication in cars or in direct sun during hot Australian summers as elevated temperatures can degrade formulations.

Cold‑Chain Logistics For Pharmacies

Temovate does not require cold‑chain transport but should be stored in temperature‑controlled rooms away from heat sources at the pharmacy.

When dispatching to remote customers, pack with insulation to avoid prolonged exposure to extreme heat and use tracked postal services where possible.

Pharmacies should rotate stock, monitor expiry dates and advise patients to inspect packaging on arrival before storing the medication promptly in a cool place.

Guidelines For Proper Use

Pharmacist Counselling Style In Australia

Adopt a structured, empathetic approach that begins by confirming the indication and any previous steroid use.

Demonstrate FTU dosing for the specific site and give a clear duration such as "apply thinly once daily for 7–14 days".

Highlight sensitive areas to avoid and document a planned follow‑up, either in‑person or by telehealth.

Provide printed or SMS treatment plans for community patients and liaise with prescribers if repeat scripts are requested.

National Health Authority Recommendations

National recommendations favour the lowest effective potency for the shortest time, clear documentation and active monitoring, particularly for children and extensive disease.

Encourage transitions to steroid‑sparing options and refer to dermatology when response is incomplete or adverse effects arise.

Delivery Across Australia